Results 11 to 20 of about 79,283 (266)
Cell Death Discovery, 2023 Lipopolysaccharide (LPS) is an endotoxin that can cause an acute inflammatory response. Nitric oxide (NO) is one of the most important innate immune system components and is synthesized by inducible NOS (iNOS) in macrophages in response to stimulation ...
Ryota Hashimoto +2 more
doaj +1 more source
Expert Opinion on Emerging Drugs, 2010 The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways.
J.A. McCubrey +15 more
openaire +6 more sources
Acta Pharmaceutica Sinica B, 2023 MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to ...
Juanjuan Feng +10 more
doaj +1 more source
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Cell Reports, 2018 Summary: Expression of aberrantly spliced BRAF V600E isoforms (BRAF V600E ΔEx) mediates resistance in 13%–30% of melanoma patients progressing on RAF inhibitors. BRAF V600E ΔEx confers resistance, in part, through enhanced dimerization.
Michael J. Vido +3 more
doaj +1 more source
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
PLoS ONE, 2019 Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, MEK inhibitors have shown substantial activity
Mark Yarchoan +8 more
doaj +1 more source
Crosstalk between PI3 Kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK Pathways Downstream PDGF Receptor
Cellular Physiology and Biochemistry, 2013 Background/Aims: Our earlier studies suggested crosstalk between IRS/PI3 kinase/PDK1/Akt/Rac1/ROCK and (Shc2/Grb2/SOS)/Ras/Raf/MEK/ERK pathways downstream PDGF-ββ receptor responsible for chemotaxis and proliferation of malignant mesothelioma cells.
Emma Tabe Eko Niba +8 more
doaj +1 more source
Scientific Reports, 2022 Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and MAPK ...
Seyed Pairawan +16 more
doaj +1 more source
PLoS ONE, 2023 Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS).
Fan Fan +10 more
doaj +3 more sources
Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
SAGE Open Medical Case Reports, 2019 Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition.
Marco AJ Iafolla +3 more
doaj +1 more source
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Cell Reports, 2019 Summary: The mitogen-activated protein kinase (MAPK) pathway is a critical effector of oncogenic RAS signaling, and MAPK pathway inhibition may be an effective combination treatment strategy. We performed genome-scale loss-of-function CRISPR-Cas9 screens
Rita Sulahian +30 more
doaj +1 more source